Immunotherapy for melanoma: The good, the bad, and the future

被引：9
作者：
Poehlein C.H. [1 ]
Rüttinger D. [1 ]
Ma J. [1 ]
Hu H.-M. [1 ]
Urba W.J. [1 ]
Fox B.A. [1 ]
机构：
[1] Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland, OR 97213
来源：
Current Oncology Reports | 2005年 / 7卷 / 5期
关键词：
Melanoma; Treg Cell; Adoptive Transfer; Antitumor Immune Response; Adoptive Immunotherapy;
D O I：
10.1007/s11912-005-0066-1
中图分类号：
学科分类号：
摘要：
The past 20 years have seen remarkable advances in our understanding of the molecular and cellular processes controlling the development of an anticancer immune response. These advances have spawned a renaissance in the field of cancer immunotherapy, the original targeted therapy, during which investigators have pushed the envelope and translated promising strategies into investigational therapeutics in patients with cancer. An approach that combined nonmyeloablative lymphodepleting chemotherapy with adoptive transfer of tumor-specific CD4 and CD8 T cells exhibited an initial objective response rate of 51% for patients with stage IV melanoma. Although this strategy is extremely challenging, one can expect technological advances that may simplify this approach and further improve outcome. Copyright © 2005 by Current Science Inc.
引用
收藏
页码：383 / 392
页数：9
相关论文
共 68 条
[21]  
Dobrzanski M.J., Reome J.B., Dutton R.W., Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection, Clin. Immunol., 98, pp. 70-84, (2001)
[22]  
Winter H., Hu H.M., Poehlein C.H., Et al., Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies, Immunology, 108, pp. 409-419, (2003)
[23]  
Poehlein C.H., Hu H.M., Yamada J., Et al., TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells, J. Immunol., 170, pp. 2004-2013, (2003)
[24]  
Lowes M.A., Bishop G.A., Crotty K., Et al., T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas, J. Invest. Dermatol., 108, pp. 914-919, (1997)
[25]  
Chu Y., Hu H.M., Winter H., Et al., Examining the immune response in sentinel lymph nodes of mice and men, Eur. J. Nucl. Med., 26, (1999)
[26]  
Meijer S.L., Dols A., Urba W.J., Et al., Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells, J. Immunother., 25, pp. 359-372, (2002)
[27]  
Tatsumi T., Kierstead L.S., Ranieri E., Et al., Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma, J. Exp. Med., 196, pp. 619-628, (2002)
[28]  
Sakaguchi S., Sakaguchi N., Asano M., Et al., Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases, J. Immunol., 155, pp. 1151-1164, (1995)
[29]  
Antony P.A., Piccirillo C.A., Akpinarli A.S., Et al., CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells, J. Immunol., 174, pp. 2591-2601, (2005)
[30]  
Chattopadhyay S., Chakraborty N.G., Mukherji B., Regulatory T cells and tumor immunity, Cancer Immunol. Immunother., (2005)
1234567